Proneurogenic Effects of Trazodone in Murine and Human Neural Progenitor Cells by Bortolotto, Valeria et al.
Proneurogenic Effects of Trazodone in Murine and Human Neural
Progenitor Cells
Valeria Bortolotto,†,§ Francesca Mancini,∥ Giorgina Mangano,∥ Rita Salem,†,§ Er Xia,†,§
Erika Del Grosso,‡,§ Michele Bianchi,‡,§ Pier Luigi Canonico,§ Lorenzo Polenzani,∥
and Mariagrazia Grilli*,†,§
†Laboratory of Neuroplasticity, ‡Laboratory of Pharmaceutical Analysis, and §Department of Pharmaceutical Sciences, University of
Piemonte Orientale “Amedeo Avogadro”, Via Bovio 6, Novara 28100, Italy
∥Angelini S.p.A, RR&D, Angelini Research Center, Piazzale della Stazione, 00071 S. Palomba-Pomezia, Roma, Italy
ABSTRACT: Several antidepressants increase adult hippocampal
neurogenesis (ahNG) in rodents, primates, and, potentially, humans.
This effect may at least partially account for their therapeutic activity.
The availability of antidepressants whose mechanism of action involves
different neurotransmitter receptors represents an opportunity for
increasing our knowledge on their distinctive peculiarities and for
dissecting the contribution of receptor subtypes in ahNG modulation.
The aim of this study was to evaluate, in vitro, the effects of the
antidepressant trazodone (TZD) on ahNG by using primary cultures of
murine adult hippocampal neural progenitor cells (ahNPCs) and human
induced pluripotent stem cell (iPSC)-derived NPCs. We demonstrated
that TZD enhances neuronal differentiation of murine as well as human
NPCs. TZD is a multimodal antidepressant, which binds with high
affinity to 5-HT2a, α1, and 5-HT1a and with lower affinity to 5-HT2c,
α2 and 5-HTT. We demonstrated that TZD proneurogenic effects were mediated by 5-HT2a antagonism both in murine and in
human NPCs and by 5-HT2c antagonism in murine cells. Moreover NF-κB p50 nuclear translocation appeared to be required for
TZD-mediated proneurogenic effects. Interestingly, TZD had no proneurogenic effects in 5-HT depleted ahNPCs. The TDZ
bell-shaped dose−response curve suggested additional effects. However, in our model 5-HT1a and α1/α2 receptors had no role in
neurogenesis. Overall, our data also demonstrated that serotoninergic neurotransmission may exert both positive and negative
effects on neuronal differentiation of ahNPCs in vitro.
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■ INTRODUCTION
Lifelong generation of new neurons takes place in the
subgranular zone (SGZ) of the dentate gyrus (DG) from a
pool of adult hippocampal neural progenitor cells (ahNPCs).1
Newly generated neurons can integrate into preexisting
neuronal networks and potentially contribute to specific
functions such as hippocampal-dependent learning and
memory, mood regulation, and stress response.2 Extensive
research efforts have contributed to the idea that adult
hippocampal neurogenesis (ahNG) represents an important
form of neural plasticity, which is deregulated in several
neuropsychiatric disorders, including major depressive disorder
(MDD), and whose reduction is correlated with cognitive
impairment and mood alterations.3−6
Adult hippocampal NG is susceptible to pharmacological
modulation.7−11 Several antidepressant drugs including tryciclic
antidepressants (TCAs), selective serotonin reuptake inhibitors
(SSRIs), and serotonin−norepinephrine reuptake inhibitors
(SNRIs), counteract stress-reduced ahNG in preclinical models
of depressive-like behavior.12,13 Increased number of hippo-
campal neural progenitors was also reported in post-mortem
studies in MDD patients treated with antidepressants.14−16
Although still debated, ahNG may be required for some of the
behavioral effects of antidepressants, at least in rodent
models.17,18
Trazodone (TDZ) is a triazolopyridine derivative that in
clinical studies has demonstrated an antidepressant activity
comparable to TCAs, SSRIs, and SNRIs.19 TZD is structurally
unrelated to other antidepressant classes and is characterized by
a unique profile.20 In the past, the drug has been classified as a
serotonin receptor antagonist and reuptake inhibitor (SARI),
able to provide simultaneous inhibition of the serotonin
transporter (SERT), partial agonism of serotonin 5-HT1a
receptors, and antagonism of 5-HT2a and 5-HT2c receptors.
With such a profile, the drug potentially avoids tolerability
issues that are often associated with 5-HT2a and 5-HT2c
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receptor stimulation (i.e., insomnia, anxiety, and sexual
dysfunction).21 In addition to those properties, TDZ also
exerts antagonistic activity against α1- and α2-adrenergic
receptors (ARs), with minimal anticholinergic effects.21 In
such respect, by taking advantage of a recently introduced
concept, TZD can be recognized as the first ever multimodal
antidepressant.22
In line with the accepted hypothesis that antidepressants may
exert their therapeutic activity at least in part via positive effects
on neurogenesis, modulation of ahNG has become part of the
discovery activities of recently approved antidepressant
drugs.23,24 In addition, promotion of adult hippocampal
neurogenesis is currently explored as a strategy for anti-
depressant drug screening.25−27 Despite intense research efforts
in this field, our current knowledge on the relative contribution
of different receptors in the modulation of ahNG and in
mediating the effects of antidepressant drugs is limited.
Extensive literature data suggest a potential and complex
contribution of receptors engaged by TZD, such as 5-HT1a, 5-
HT2a and 5-HT2c, α1, and α2, in the modulation of adult
neurogenesis.28−30 How the unique pharmacological profile of
TZD may impact adult neurogenesis is therefore of interest and
could potentially increase our understanding of ahNG
modulation by neurotransmitters.
■ RESULTS AND DISCUSSION
Serotonin Promotes Neuronal Differentiation of
Adult Hippocampal NPCs. For our studies, we used a well
characterized in vitro model of murine ahNPCs. In this
experimental setting, when ahNPCs from the adult mouse
hippocampus are grown in the presence of growth factors, they
are phenotypically characterized by expression of nestin and
SRY-related HMG-box gene 2 (SOX2), bonafide markers of
undifferentiated neural progenitors, and by the absence of
markers of mature and immature neurons such as MAP-2, Tuj-
1, and doublecortin.27 Upon removal of growth factors and
exposure to a serum-free defined medium, ahNPCs stop
dividing and differentiate onto laminin-coated chamber slides.
By double immunolabeling for markers of neurons (MAP-2)
and undifferentiated ahNPCs (nestin), the appearance of new
neurons that are MAP-2+ and nestin− and newly generated
neuroblasts (cells positive for both MAP-2 and nestin) can be
evaluated and quantified as previously described.26 Under these
experimental conditions, within 24 h, ahNPCs give rise to
about 2% and 30% of neurons and neuroblasts, respectively
(Figure 1a,b). We initially exposed ahNPCs to increasing
concentrations of the endogenous neurotransmitter 5-HT
(0.0001−100 μM). As depicted in Figure 1, 5-HT is able to
significantly increase the percentage of newly generated
neurons and neuroblasts compared to vehicle-treated cells (p
< 0.001, ANOVA, Figure 1a,b). Altogether these data confirm
that in our in vitro model ahNPC differentiation is positively
modulated by 5-HT levels, in line with previous reports.31
TZD Promotes Neuronal but Not Glial Differentiation
of ahNPCs in Vitro. Subsequently, ahNPCs were differentiated
in the presence of a wide range of TZD concentrations
(0.0003−1 μM) for 24 h. Such concentration range was chosen
with the purpose of studying the potential involvement of all
receptor subtypes bound with high and low affinity by TZD.21
Compared to vehicle-treated cells, a significant increase in the
percentage of MAP-2+ and nestin− cells was observed in the
presence of 0.01−0.3 μM TZD (0.1 μM TZD, p < 0.001 vs
vehicle, ANOVA, Figure 2a), suggesting that the drug is able to
promote neuronal differentiation of murine ahNPCs in a
concentration-dependent manner. Interestingly, at the highest
concentration (1 μM) TZD was ineffective, suggesting that at
that concentration, the drug may activate mechanisms or
receptors that potentially counteract those promoting neuro-
genesis at lower concentrations. Similar effects were obtained
by the drug on the population of MAP-2+/nestin+ neuroblasts
(data not shown). We also tested the effects of maximally
effective concentrations of TZD (100 nM) and 5-HT (1 μM),
in comparison with vehicle, as a function of exposure time (2,
12, 24, and 48 h). In the presence of vehicle, the number of
neurons (and neuroblasts, data not shown) progressively
increased with time. When we analyzed the number of newly
generated MAP-2+/nestin− neurons, in comparison with
vehicle, 5-HT promoted a significant increase at 12 and 24 h
but not at 48 h (12 h, p < 0.05; 24 h, p < 0.001, ANOVA,
Figure 2b). Compared with 5-HT, TZD proneurogenic effects
appeared slightly delayed but longer lasting and more
pronounced, with a significantly higher number of neurons
generated at 24 and 48 h (% of MAP-2+/nestin− cells: 24 h, 5-
HT 6.1 ± 0.7, TZD 8.9 ± 0.4, p < 0.01 vs 5-HT-treated cells;
48 h, 5-HT 9.1 ± 0.7, TZD 14.3 ± 1.3, p < 0.001 vs 5-HT
treated cells, ANOVA, Figure 2b).
In absence of growth factors, ahNPCs can also differentiate
toward non-neuronal lineages. Interestingly, 24 h exposure of
ahNPCs to TZD (0.0003−1 μM) affected neither the
percentage of newly generated GFAP+ astrocytes (Figure 2c)
nor the percentage of NG2+ oligodendrocyte precursors
(Figure 2d). In order to investigate whether TZD may affect
survival of NPCs and their progeny, we also analyzed apoptotic
and necrotic rate in our cell culture. As shown in Figure 2e, the
percentage of apoptotic cells was not significantly different in
TZD- versus vehicle-treated conditions. Similarly, no difference
was observed in the number of necrotic cells, as established by
disrupted membrane integrity in vehicle- vs TZD-treated
ahNPC cultures (Figure 2f). Some antidepressants are also
positive modulators of NPC proliferation.15 We tested the
Figure 1. 5-HT promotes neuronal differentiation of murine ahNPCs
in vitro. Adult hippocampal NPCs were treated with 5-HT (0.0001−
100 μM) or vehicle, for 24 h. Effects on the percentage of MAP-2+/
nestin− (a) and MAP-2+/nestin+ (b) cells generated from ahNPCs
were evaluated. Data are expressed as mean ± SD: **p < 0.01, ***p <
0.001 vs vehicle-treated cells (one-way ANOVA, Tukey’s post hoc).
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effect of TZD on the proliferation rate of ahNPCs, using
epidermal growth factor (EGF) as a positive control. At all
tested concentrations, 72 h-exposure to TZD had no effect on
ahNPC proliferation rate (Figure 2g). Overall, these data
suggested that (i) TZD effects on ahNPC neuronal differ-
entiation do not occur at the expense of NPC differentiation
Figure 2. Effects of TZD on murine ahNPC differentiation, survival, and proliferation. Adult hippocampal NPCs were treated with TZD at the
indicated concentrations or vehicle for 24 h. (a) TZD effects on the percentage of MAP-2+/nestin− cells generated from ahNPCs. (b) Time course
analysis of the proneurogenic effects of TZD and 5-HT. The percentage of MAP-2+ cells generated in the presence of TZD (100 nM) and 5-HT (1
μM) was assessed after 2, 12, 24, and 48 h of treatment. Data are expressed as mean ± SD: *p < 0.05, ***p < 0.001 vs vehicle-treated cells; ##p <
0.01, ###p < 0.001 vs 5-HT-treated cells (One-way ANOVA, Tukey’s post hoc). (c,d) Evaluation of TZD effect on the percentage of newly generated
GFAP+ astrocytes (c) and NG2+ oligodendrocyte precursors (d). (e) Assessment of TZD effect on the apoptotic rate of ahNPCs and their progeny.
Data are expressed as the percentage of apototic cells over the total number of cells. (f) Evaluation of TZD cytotoxic effect; 0.8% Triton X-100 was
used as positive control (TX100). (g) Evaluation of TZD effect on ahNPC proliferation. Epidermal growth factor (EGF, 20 ng/mL) was used as
positive control. Data are expressed as mean ± SD: ***p < 0.001 vs vehicle-treated cells (one-way ANOVA, Tukey’s post hoc).
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toward glial lineages and (ii) the effect of TZD is merely
differentiative in nature, since neither neuroprotective nor
proliferative activity was elicited by the drug on ahNPC
cultures.
The Proneurogenic Effects of TZD Are Mediated by 5-
HT2a Antagonism. We investigated the receptor subtypes
involved in the proneurogenic effect of TZD. TZD binds with
high affinity to 5-HT2a, α1, and 5-HT1a and with lower affinity
to 5-HT2c, α2, and 5-HTT.
20,21 We first evaluated the
involvement of 5-HT2a receptors in TZD-mediated effect.
When tested in ahNPC cultures, 10 nM TCB-2, a selective 5-
HT2a agonist [Ki(5‑HT2a), 0.73 nM], produced a rightward shift
in TZD concentration−response curve, while the compound
was inactive per se (Figure 3a). These data suggested that the
proneurogenic effects elicited by TZD are mediated by its
antagonistic activity at 5-HT2a receptors. To further support the
contribution of 5-HT2a receptors in TZD proneurogenic effects,
1−30 nM 4F4PP, a 5-HT2a selective antagonist, [Ki(5‑HT2a) 4
nM] and 0.3−100 nM ketanserin [a 5-HT2a and 5-HT2c
antagonist, Ki(5‑HT2a) 3.6 nM, Ki(5‑HT2c) 200 nM], were both
capable of promoting neuronal differentiation of ahNPCs in a
concentration-dependent manner (ANOVA; Figure 3b,c).
Interestingly, as shown for TZD, also for these drugs, we
observed an inverted U-shaped response curve.
At first sight, the finding that antagonism at 5-HT2a receptors
may promote neurogenesis may be surprising, given the vast
plethora of data supporting the view of 5-HT as an endogenous
positive modulator of adult hippocampal neurogenesis,32−34 in
line with its proneurogenic effect in our experimental model.
However, literature data on a role of 5-HT specific receptor
subtypes in the regulation of neurogenesis also support the idea
of distinct and even opposite effects on neurogenesis.35 In
particular, in vivo data suggested oppositional effects of
serotonin receptors 5-HT1a and 5-HT2 in the regulation of
Figure 3. TZD proneurogenic activity in murine ahNPCs is mediated by 5-HT2a antagonism. Effects of the selective 5-HT2a agonist TCB-2 (10 nM)
on TZD-mediated increase of newly generated MAP-2+ cells. (b) Effects of 4F4PP (0.3−100 nM), selective 5-HT2a antagonist, and (c) ketanserin
(0.1−300 nM), a nonselective 5-HT2 antagonist, on ahNPC differentiation toward the neuronal lineage. Data are expressed as mean ± SD: *p <
0.05, **p < 0.01, ***p < 0.001 vs vehicle-treated cells; #p < 0.05 vs 30 nM TZD-treated cells. §§p < 0.01 vs 100 nM TZD-treated cells (one-way
ANOVA, Tukey’s post hoc).
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adult hippocampal neurogenesis.35 Unfortunately, in several
reports these data appear contradictory, in part probably due to
limited selectivity of utilized agonists and antagonists. Klempin
et al.,35 by using cinanserin as a nonselective 5-HT2 antagonist
in vivo, demonstrated that it acutely produces an increase in cell
proliferation in hippocampus. When the same authors tested
the nonselective 5-HT2 agonist α-methyl-5-HT, a net decrease
in the number of BrdU+ cells was found. Phenotypic analysis
for 5-HT2 agonist treatment revealed a net decrease in type 1,
2a, and 2b cells after acute treatment and a significantly reduced
number of newborn neurons after 7 days of treatment.
Surprisingly, the same authors showed that in vitro blockade
of 5-HT2 receptors by cinanserin in NPC cultures produced a
significant reduction in the number of βIII-tubulin positive
cells, which represent newly generated neuroblasts.35 Even
more confusing, a similar result was obtained upon incubation
with the nonselective agonist α-methyl-5-HT. Kemplin’s data
are in contrast to those obtained by Banasr et al.33 who showed
that the nonselective 5-HT2a and 5-HT2c antagonist ketanserin
produced a decrease in the number of BrdU-labeled cells
whereas the 5-HT2a and 5-HT2c agonist DOI did not change
cell proliferation. Similarly, Jha et al.28 demonstrated an
enhanced adult hippocampal progenitor proliferation as a
result of a sustained blockade of the 5-HT2a and 5-HT2c
receptors by ketanserin treatment in mice. In our experimental
setting, we could confirm that TZD but also a selective 5-HT2a
antagonist promote neuronal differentiation of ahNPCs and
that TZD proneurogenic effects are counteracted in the
presence of a selective 5-HT2a agonist. Based on these findings,
herein we suggest that 5-HT2a antagonism may have a
Figure 4. Neuronal differentiation of human iPSC-derived NPC is increased in the presence of 5-HT and of TZD: drug activity is mediated by 5-
HT2a antagonism. (a) Effect of 28 day-long 5-HT treatment (0.0001−100 μM) on the percentage of MAP-2+ cells generated from human NPCs,
compared to vehicle. (b) Effect of 28 day-long TZD treatment (0.001−1 μM) on the percentage of MAP-2+ cells generated from human NPCs,
compared to vehicle. (c, d) Representative confocal microscopy images for MAP-2 immunolabeling (green) of human NPCs in the presence of
vehicle (c) and TZD 100 nM (d). Nuclei are counterstained with Hoechst (blue). Magnification = ×40; Scale bar 20 μM. Effect of TZD treatment
on the differentiation of human NPCs toward astroglial lineages (e, f), as indicated by the percentages of GFAP (e) and S100B (f) immunopositive
cells. (g) Effect of the selective 5-HT2a agonist TCB-2 (10 nM) on TZD-mediated effects. (h) Evaluation of the percentage of in vitro generated
MAP-2+ cells in the presence of the selective 5-HT2a antagonist 4F4PP (0.3−30 nM). Data are expressed as mean ± SD: *p < 0.05, **p < 0.01, ***p
< 0.001 vs vehicle-treated cells (one-way ANOVA, Tukey post hoc).
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significant role in neuronal differentiation of ahNPCs, at least in
vitro, and that TZD may act, at least in part, via this mechanism
to promote neurogenesis. Recently, another novel pharmaco-
logical activity was described for TZD in a model of human
neuronal cells, namely, its neuroprotective effects against
inflammatory insults.36 Interestingly, also this TZD-mediated
effect involved antagonism at 5-HT2a receptors, since it was
counteracted by (R)-DOI.36
5-HT2a-Mediated Proneurogenic Effects of TZD in
Human Induced Pluripotent Stem Cell (iPSC)-Derived
NPCs. Very little is known about the effects elicited in vitro by
antidepressant drugs in human neural progenitor cells. We
tested the proneurogenic activity of 5-HT on NPCs generated
from a human iPSC line. Human iPSC-derived NPCs were
differentiated in the absence of growth factors and in the
presence of vehicle or 5-HT (0.0001−100 μM) for 28 days. A
significant increase in the percentage of MAP-2+ cells was
observed at all tested 5-HT concentrations (ANOVA, Figure
4a). In the same experimental setting, we evaluated the effect of
TZD. As shown in Figure 4b, similarly to 5-HT, TZD
significantly increased the percentage of newly generated MAP-
2+ cells (0.1 μM TZD, p < 0.01, ANOVA, Figure 4b−d). As
demonstrated in murine cells, TZD produced no significant
effect on human NPC differentiation toward the astroglial
lineage, as measured by GFAP (Figure 4e) and S100B
immunostaining (Figure 4f). Based on the results obtained
on murine ahNPCs, we then tested the effect of TZD (1−10
nM) in the presence of the selective 5-HT2a receptor agonist
TCB-2 (10 nM). TCB-2 completely counteracted the effect of
TZD (Figure 4g), suggesting that, as in murine ahNPCs, also in
human NPCs TZD promotes neuronal differentiation via 5-
HT2a antagonism. To further confirm this hypothesis, the
Figure 5. 5-HT2c, but not 5-HT1a and α1/α2 adrenergic receptors, contribute to the proneurogenic effects of TZD in murine ahNPC. (a) Effect of
the α1 agonist phenylephrine hydrochloride (Phe) on TZD proneurogenic effects. (b) Effect of the α2 antagonist idazoxan (0.001−1 μM) on
neuronal differentiation of ahNPCs. (c) Effect of the 5-HT1a agonist 8-OH-DPAT (0.1−10 nM) on neuronal differentiation of ahNPCs. (d)
Evaluation of the effect of pretreatment of ahNPCs with the selective 5-HT1a antagonist NAD299 (30 nM) on TZD-mediated proneurogenic effects.
(e) Effect of the selective 5-HT2c agonist WAY161503 (10 nM) on TZD-mediated increase of newly generated MAP-2
+ cells. (f) Evaluation of the
percentage of newly generated neurons in the presence of the 5-HT2c antagonist RS102221 (0.3−300 nM). Data are expressed as mean ± SD: **p <
0.01, ***p < 0.001 vs vehicle-treated cells; ##p < 0.01 vs 30 nM TZD-treated cells; §§§p < 0.001 vs 100 nM TZD-treated cells (one-way ANOVA,
Tukey’s post hoc).
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selective 5-HT2a antagonist 4F4PP (3−30 nM) significantly
increased the percentage of MAP-2+ cells generated in vitro,
when compared to vehicle-treated cells (ANOVA, Figure 4h).
Evaluation of the Involvement of Other Receptor
Subtypes in TZD-Mediated Proneurogenic Effects: A
Potential Role for 5-HT2c Receptors. In light of the
multimodal mechanism of action of TZD, we further expanded
our investigation. TZD indeed binds with high affinity also α1
and 5-HT1a receptors.
21 Previous data in our laboratory
suggested that α1 antagonists like doxazosin could promote in
vitro neuronal differentiation of ahNPCs.30 However, when the
α1 agonist phenylephrine hydrocloride (30−100 nM) was
tested in the presence of TZD, it did not counteract its
proneurogenic effects in ahNPC cultures (Figure 5a). Although
with low affinity, TZD also exerts antagonistic activity at α2
receptors.21 Blockade of this receptor subtype has been
demonstrated to accelerate the proneurogenic effects of chronic
antidepressant treatment.37 Based on these observations and on
a previous report of a noradrenergic tone in our cellular
model,30 we then tested idazoxan (0.001−1 μM), an α2
antagonist [Ki(α2a) 10 nM; Ki(α2b) 100 nM]. In our experimental
setting, idazoxan was devoid of proneurogenic effects on
ahNPCs (Figure 5b). Altogether these data strongly suggested
the lack of involvement of both α1 and α2 receptors in TZD
proneurogenic activity in vitro.
A vast array of information suggested that 5-HT1a may be the
predominant receptor for antidepressant activity and, more
recently, also for serotonin-mediated regulation of hippocampal
neurogenesis in vivo.38−40 Although our cellular model
expressed 5-HT1a receptor mRNA (data not shown), when
murine ahNPCs were exposed to the 5-HT1a agonist 8-OH-
DPAT [Ki(5‑HT1a) 1.78 nM; 0.1−10 nM], we did not observe
any proneurogenic effect (Figure 5c), suggesting that 5-HT1a
receptors may not be involved in neuronal differentiation
elicited by TZD and even by 5-HT. To further corroborate this
finding, the selective 5-HT1a antagonist NAD299 [Ki(5‑HT1a) 0.6
nM; 30 nM] had no effect on the proneurogenic response
elicited by 100 nM TZD (Figure 5d). NAD299 alone had no
effect on ahNPC neuronal differentiation (Figure 5d). Of note,
also human NPCs expressed 5-HT1a mRNA, but as in murine
ahNPCs, we could not observe any effect of NAD299 on TZD-
mediated effects on these cells (data not shown). The lack of
involvement of 5-HT1a receptors in TZD-mediated neuronal
differentiation of both murine and human NPCs is in
agreement with previously published data suggesting that 5-
HT1a receptor subtype is not involved in modulation of ahNPC
differentiation but rather in their proliferation. In line with our
results, two 5-HT1a agonists, 8-OH-DPAT and ipsapirone,
failed to regulate neuronal differentiation of NPCs in vitro.35
Conversely, in vivo blockade of 5-HT1a receptors significantly
reduced the number of proliferating ahNPCs in rat dentate
gyrus.41 Moreover, after serotonin depletion by para-
chlorophenylalanine (PCPA), an irreversible inhibitor of the
synthetizing enzyme TPH2, treatment with 8-OH-DPAT could
Figure 6. TZD proneurogenic activity requires synthesis of endogenous 5-HT by murine ahNPC. (a) LC-ESI-MS analysis of extracellular 5-HT
content in our in vitro model under basal conditions and after treatment with 1 μM fluoxetine (FLX) and 100 nM TZD. (b) Effect of fluoxetine
(0.0003−3 μM) on the percentage of MAP-2+ cells generated from ahNPCs. Data are expressed as mean ± SD: ***p < 0.001 vs vehicle-treted cells
(one-way ANOVA, Tukey’s post hoc). (c) Effect of irreversible inhibition of tryptophan hydroxylase by para-chlorophenylalanine (PCPA, 50 μM, 3
day-treatment of proliferating ahNPCs) on the proneurogenic activity by TZD. Evaluation of exogenous 5-HT (1 μM) treatment on neuronal
differentiation of both PCPA-treated and vehicle-treated ahNPCs. Data are expressed as mean ± SD: ***p < 0.001 vs basal condition in vehicle-
treated cells; §§§p < 0.001 vs basal condition in PCPA-treated cells (one-way ANOVA, Tukey’s post hoc); ##p < 0.01 vs basal condition in vehicle-
treated cells (Student’s t test).
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rescue the number of proliferative ahNPC BrdU+ in the dentate
gyrus.33 Similarly, in vitro, PCPA treatment and a 5-HT1aR
antagonist hampered proliferation but not differentiation of
ahNPCs.42 Again, NPC proliferation was restored after
treatment with 5-HT or a 5-HT1a receptor agonist.
42
Interestingly, in a different model of human neuronal cells
where TZD elicited neuroprotective effects against inflamma-
tory insults, the antidepressant drug activated ERK phosphor-
ylation and BDNF gene transcription, and this effect appeared
to be mediated by activation of 5-HT1a receptors.
36
TZD binds, although with low affinity, also 5-HT2c receptors.
When tested in murine ahNPC cultures, the selective 5-HT2c
agonist WAY161503 [Ki(5‑HT2c) 4 nM] produced a rightward
shift in TZD concentration−response curve (Figure 5e). WAY
was inactive per se (Figure 5e). These data suggested that the
proneurogenic effects elicited by TZD are also mediated by its
antagonistic activity at 5-HT2c receptors. To confirm our
observation, we differentiated murine ahNPCs in the presence
of 0.3−300 nM RS102221, a 5-HT2c selective antagonist
[Ki(5‑HT2c) 10 nM]. RS102221 significantly increased the
percentage of MAP-2+ cells (10 nM RS102221, p < 0.001,
ANOVA, Figure 5f). These in vitro results are in line with the
observation that the antidepressant drug agomelatine can
promote hippocampal neurogenesis both via melatonergic
agonistic activity and 5-HT2c antagonism in rodents.
23
Altogether these data suggest (i) the lack of involvement of
5-HT1a, α1 and α2 receptors in TZD proneurogenic activity in
vitro and (ii) a possible involvement of 5-HT2c antagonism in
TZD effect, at least in murine cells. Indeed we failed to
demonstrate 5-HT2c mRNA expression in human iPSC-derived
NPCs (data not shown).
The in Vitro Proneurogenic Effects of TZD Require 5-
HT Synthesis by Murine ahNPCs. The fact that TZD
exerted its effects via 5-HT2a and 5-HT2c antagonism supported
the idea of an endogenous serotoninergic tone in our in vitro
model and also raised the question of serotonin source both
under basal conditions and in response to TZD. We measured,
by LC-ESI-MS, extracellular 5-HT concentration in our murine
cultures. Values were, on average, 0.86 ± 0.19 ng/mL (Figure
6a), corresponding to 4.9 ± 1.1 nM. Interestingly, murine and
human ahNPCs not only express several 5-HT receptors but
also 5-HTT.35,42 TZD is a low affinity 5-HTT blocker,21 and
this drug activity can result in an increased availability of
extracellular 5-HT. Interestingly, a slight, although not
statistically significant, increase in 5-HT extracellular concen-
tration was observed in the presence of a proneurogenic
concentration of 100 nM TZD compared to vehicle (TZD 1.25
± 0.20 ng/mL, vehicle 0.86 ± 0.19 ng/mL, p = 0.07, Figure 6a).
Under the same experimental conditions, the SSRI anti-
depressant fluoxetine (0.003−3 μM) promotes neuronal
differentiation of murine ahNPCs in a concentration-dependent
manner (p < 0.001, ANOVA, Figure 6b). The proneurogenic
effect of fluoxetine correlated with a significant increase in 5-
HT extracellular concentration, compared with vehicle-treated
conditions (1 μM FLX 1.76 ± 0.1 ng/mL, p < 0.01 vs vehicle, t
test), suggesting that our cellular model indeed does express
functional 5-HTT (Figure 6a). Undifferentiated ahNPCs also
express both isoforms of tryptophane hydroxylase, TPH1 and
TPH2.42 We performed a three-day treatment of proliferating
ahNPCs with 50 μM PCPA to irreversibly inhibit TPH and
deplete ahNPCs of endogenous serotonin.42 As expected,
extracellular 5-HT levels became undetectable by LC-ESI-MS
in culture medium of PCPA-treated compared to vehicle-
treated cells. Although literature data report that PCPA
treatment significantly decreases proliferation of ahNPCs
both in vitro and in vivo,42,43 in our hands, blockade of 5-HT
synthesis caused a small but not statistically significant
reduction (about −23%) in the number of recovered PCPA-
treated NPCs compared to vehicle-treated cells, suggesting a
more limited effect of 5-HT depletion on ahNPC proliferation.
Similarly, PCPA treatment did not affect the survival of
ahNPCs (% dead cells/total cells, 12.9 ± 2.5 and 16.2 ± 2.9 in
vehicle- and PCPA-treated cells, respectively, p > 0.05, t test).
After PCPA or vehicle treatment, ahNPCs were washed and
plated at the same cellular density, under conditions promoting
neuronal differentiation in the presence of either TZD (30−300
nM) or the corresponding vehicle. The percentage of newly
generated MAP-2+ cells was then determined in vehicle- and
PCPA-treated cells. Under basal conditions, we observed a
statistically significant reduction in the percentage of MAP-2+
cells in PCPA-treated cells compared to vehicle-treated cells
(Figure 6c, −59.1%, p < 0.01, t test). This effect cannot be
ascribed to a reduction in cell viability since we did not observe
significant differences in the apoptotic or necrotic rate of
ahNPCs and their progeny under the same experimental
conditions (data not shown). Even more interestingly, 30−300
nM TZD promoted neuronal differentiation in vehicle-treated
but not in PCPA-treated ahNPCs (Figure 6c). As a control,
exogenously added 5-HT (1 μM) promoted neurogenesis in
both vehicle- and PCPA-treated ahNPCs (p < 0.001 vs vehicle,
ANOVA Figure 6c), suggesting that PCPA-treated cells were
not affected in their ability to respond to proneurogenic signals.
Figure 7. NF-κB p50 nuclear translocation is required for TZD but not for 5-HT proneurogeic effect. (a) Effect of TZD after inhibition of NF-κB
p50 nuclear translocation. Data are expressed as mean ± SD: ***p < 0.001 vs vehicle treated cells. (b) 5-HT proneurogenic activity in the presence
of NF-κB p50 nuclear translocation inhibition. Data are expressed as mean ± SD: ***p < 0.001 vs vehicle treated cells (one-way ANOVA, Tukey’s
post hoc).
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Of note, although not significantly different, the percent of
increase of MAP-2+ cells over basal differentiating conditions
was higher in PCPA-treated compared to vehicle-treated
ahNPCs (+260.9 ± 83.9 and +127.2 ± 32.3% in PCPA- and
vehicle-treated cells, respectively, p = 0.062, t test; Figure 6c).
Altogether, these data strongly support the finding that the
effects of TZD on neuronal differentiation of ahNPCs are
mediated by drug antagonism at 5-HT2 receptors, in the
presence of a serotoninergic tone, which, in our experimental
setting, is not significantly affected by the antidepressant drug.
Nuclear Translocation of NF-κB p50 Is Required for
the Proneurogenic Effects Elicited by TZD. Based on the
current results, our working hypothesis is that 5-HT exerts
proneurogenic and antineurogenic effects by interacting with
different serotonergic receptor subtypes. While the 5-HT
receptors responsible for the serotonin proneurogenic effect
in the present model remain to be clarified, we investigated
which downstream signaling pathways could play a role in the
TZD effect mediated by 5-HT2a and 5-HT2c receptor subtypes.
Previous data from our laboratory established the relevance of
NF-κB proteins, and in particular of the p50 subunit, in the in
vitro and in vivo proneurogenic effect of several drugs26,27 as
well as of neural mediators.44−46 Based on these data, we tested
the involvement of NF-κB p50 in TZD-mediated proneuro-
genic effects on ahNPCs. Interestingly, cotreatment of ahNPCs
with SN50 (10 μg/mL), an inhibitor of NF-κB p50 nuclear
translocation, completely counteracted the proneurogenic
effects of 1, 10, and 100 nM TZD (Figure 7a).
However, unlike TZD, in same experimental setting the
enhancement of the proneurogenic effect obtained by adding
external 5-HT did not require NF-κB p50 nuclear translocation
(Figure 7b). These results would need additional studies to
further characterize the signaling pathways that operate
downstream the different 5-HT receptor subtypes and their
balance in producing the proneurogenic effects of 5-HT and
trazodone.
■ CONCLUSIONS
This in vitro study suggests, for the first time, a new
pharmacological activity of TZD, namely, its ability to promote
neuronal differentiation of murine and human NPC. An
extensive pharmacological characterization of receptors in-
volved in TZD proneurogenic activity in murine cells revealed
that 5-HT2a and 5-HT2c antagonism is mainly responsible for
that effect. Interestingly, also in iPSC-derived human NPCs, the
antidepressant drug promotes neuronal differentiation via
blockade of 5-HT2a receptors. This piece of information is
quite important since most in vitro studies evaluating the
activity of clinically relevant drugs on neurogenesis have been
performed in rodent cells. Moreover in our hands, unlike the
SSRI fluoxetine, the proneurogenic effects of TZD did not
appear to correlate with an increase in 5-HT extracellular
concentration, as a result of 5-HTT blockade. Finally, our data
add further complexity to the role played by serotoninergic
neurotransmission in the regulation of adult hippocampal
neurogenesis. Previous in vivo data suggested oppositional
effects of serotonin receptors 5-HT1a and 5-HT2 in the
regulation of adult hippocampal neurogenesis.35 Although
obtained in vitro, our data also support the concept that
serotonin, acting on different receptor subtypes, may promote
but also counteract via 5-HT2 receptors neuronal differentiation
of adult NPCs. Despite the widespread view of 5-HT as an
endogenous positive modulator of hippocampal neurogenesis,
it is not surprising that homeostasis within this process may be
reached also by oppositive effects via different receptor
subtypes. In our experimental setting, we could not
demonstrate that 5-HT1a receptors may play a role in the
positive modulation of ahNG either in murine or in human
cells, so at this stage we cannot point to the receptor subtype
that mediates the in vitro proneurogenic effects of 5-HT in
these cells. Based on literature reports, 5-HT4 is known to
promote neurogenesis both in vitro and in vivo,47,48 but mRNA
for that receptor subtype was not expressed in our cellular
model (data not shown). The other receptor subtype that has
been proposed to play a role in neurogenesis is the ionotropic
5-HT3, although conflicting results have been obtained since
both activation and blockade of that receptor have been
proposed to promote neuronal differentiation of ahNPCs.49,50
Again, mRNA for this receptor subtype was not detected in our
model (data not shown).
Interestingly, at least in murine cells, in our experimental
setting the time course of TZD proneurogenic effects was also
different compared to that of 5-HT, again pointing to
differences in the overall effects on neurogenesis of molecules
that act via distinct receptor subtypes. The different time course
profile of TZD and 5-HT could be also potentially explained by
changes in receptor subtype expression by ahNPCs and their
progeny over time in vitro. Such changes could even be
triggered differently by TZD or 5-HT during in vitro cell
maturation stages. For these reasons, future studies will need to
further explore the differential contribution of distinct 5-HT
receptors on NPCs and their progeny and their overall impact
on adult hippocampal neurogenesis.
■ METHODS
Animals. Male C57BL/6 (C57BL/6, The Jackson Laboratories,
US) mice were acclimated under light- and temperature-controlled
conditions in high efficiency particulate air (HEPA)-filtered Thoren
units (Thoren Caging System, Hazelton, PA). Mice were housed in
numbers of 3−4/cage with ad libitum access to food and water at the
animal facility of Piemonte Orientale University. Animal care and
handling were carried out according to protocols approved by the
European Community Directive and the local Institutional Animal
Care and Use Committees (IACUC).
Drugs. All drug concentrations were chosen based on binding
affinity to their target receptors. The source of compounds was as
follows: 5-hydroxytryptamine hydrochloride (5-HT), trazodone
hydrochloride (TZD), ketanserin (+) tartrate salt, DL-p-chloropheny-
lalanine (PCPA), phenylephrine hydrochloride (Phe), and fluoxetine
hydrochloride were purchased from Sigma-Aldrich (Milan, Italy);
4F4PP oxalate, RS102221 hydrochloride, R-(+)-8-hydroxy-DPAT
hydrobromide (8-OH-DPAT), WAY161503 hydrochloride, TCB-2,
NAD299 hydrochloride, and idazoxan hydrochloride were purchased
from Tocris (Bioscience, Bristol, UK).
Isolation and Culture of Adult Hippocampal Neural
Progenitor Cells (ahNPCs). Adult murine hippocampal NPC
isolation was performed as previously described.30 Briefly, for each
culture preparation, three adult male mice (3−4 month-old) were
euthanized by cervical dislocation, and their hippocampi were
dissected. Tissue was digested with a Papain Dissociation System
(Worthington DBA, Lakewood, NJ). Cells were plated in NUNC
EasyFlask 25 cm2 (Thermo Scientific, Waltham, MA) and cultured in
serum-free complete proliferation medium [Neurobasal-A with B27
supplement, 2 mM glutamine (Gibco, Life Technologies, Monza, IT),
20 ng/mL recombinant human epidermal growth factor (rhEGF), 10
ng/mL recombinant human fibroblast growth factor-2 (rhFGF-2,
PeproTech, Rocky Hill, NJ), and 4 μg/mL heparin sodium salt
(Sigma-Aldrich)]. Passage 1 (P1) neurospheres were dissociated for
the first time after 10 days in vitro (DIV). From P2, dissociation was
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performed every 5 days, and NPCs were replated at a density of 12 000
cells/cm2. NPCs were used for proliferation and differentiation
experiments from P5 to P30. Proliferating NPCs were routinely
tested for their undifferentiated state by expression of SOX2 (Sry-
related HMG box transcription factor) and nestin (type VI
intermediate filament). For irreversible inhibition of tryptophane
hydroxylase (TPH), cells were treated with 50 μM of PCPA or vehicle
for 72 h starting from the second day after dissociation. At day 5, cells
were dissociated and plated for differentation.
Human iPSC-Derived Neural Progenitor Cell Culture. Human
NPC derived from human induced pluripotent stem cells (hiPSCs)
generated by genome footprint-free episomal reprogramming method
were purchased from 101 Bio (Palo Alto, CA). hNSCs were cultured
in DMEM/F12 complete medium supplemented with B27 and N2
(Gibco), GlutaMax (Gibco), 20 ng/mL rhEGF, 20 ng/mL rhFGF-2, 2
μg/mL heparin, and 100 U of penicillin and 100 μg/mL streptomycin.
Every 4 days (80% confluence), hNSCs were dissociated with StemPro
Accutase (Thermo Fisher, Life Technologies) at 37 °C for 4 min.
Single cells were harvested by centrifugation at 1000g, counted, and
seeded onto Geltrex LDEV-Free hESC-qualified (Invitrogen, Life
Technologies) coated dishes (3.5 cm, BD Falcon) at a density of
52 000 cells/cm2. hNSC cultures were maintained at 37 °C, 95%
humidity, 5% CO2, and received daily medium changes. From P5 to
P14 cells were used for differentiation.
Mouse Hippocampal NPC Proliferation and Differentiation.
For evaluation of cell proliferation, dissociated NPCs were seeded
onto flat bottom 96-well plates (Falcon) at a density of 4000 cells/
well. Standard medium for basal conditions contained Neurobasal-A,
B27, 2 mM glutamine, 10 ng/mL hbFGF-2, 4 μg/mL heparin, and 100
U of penicillin and 100 μg/mL streptomycin. Cells were treated with
indicated drug concentration or corresponding vehicle and incubated
in a humidified atmosphere at 37 °C with 5% CO2. Complete
proliferation medium with rhEGF (20 ng/mL) was included as
positive control. After 72 h, proliferation rates were determined using
CellTiter-Glo luminescent cell viability assay (Promega), according to
manufacturer’s instructions. Values were normalized to standard
medium values. For NPC differentiation, the detailed procedure was
previously described.43 Briefly, single NPC cells were plated onto
laminin-coated Lab-Tek 8-well Permanox chamber slides (Nunc) in
differentiation medium containing Neurobasal-A, B27, and 2 mM
glutamine at a density of 43 750 cells/cm2. NPCs were treated with
indicated drug concentrations or corresponding vehicle for 24 h. To
investigate the involvement of different receptors in trazodone or
serotonin effects, cells were treated for 30 min with selective agonists
or antagonists before addition of the drug. For inhibition of NF-κB
p50 nuclear translocation, NPCs were treated with 10 μg/mL SN-50
peptide (Calbiochem) for 30 min before addition of 5-HT or TZD.
hNSC Differentiation and Drug Treatment. hNSCs were
cultured onto Geltrex coated Lab-Tek 8-well Permanox chamber
slides (Nunc) at a density of 25 000 cells/cm2 in 200 μL of complete
medium. Cells were allowed to attach for 6 h, then medium was
replaced by differentiation medium [DMEM/F12, B27 and N2
supplements, Glutamax, nonessential amino acids (NEAA, Sigma-
Aldrich), 200 nM ascorbic acid (Stemcells technologies, FR), and 1349
g/L glucose (Sigma-Aldrich)] containing vehicle or drug treatment.
Every 4 days medium was half changed with fresh differentiation
medium.
Immunolocalization Studies in Differentiated Murine and
Human NPCs. After differentiation, cells were fixed with 4%
paraformaldehyde/4% saccharose solution (Sigma) and processed
for immunocytochemistry as detailed elsewhere.30 Primary antibodies
were as follows: anti-microtubule-associated protein-2 (MAP-2; rabbit
polyclonal, 1:600; Millipore, Milan, IT), anti-nestin (chicken
monoclonal, 1:1500; Neuromics, DBA, IT), anti-glial fibrillary acidic
protein (GFAP, mouse polyclonal, 1:600, Millipore), anti-chondroitin
sulfate proteoglycan (NG2, rabbit polyclonal, 1:500, Millipore), anti-
S100B (rabbit polyclonal, 1:1000, Dako, DBA, IT). Secondary
antibodies were as follows: Alexa Fluor 555-conjugated goat anti-
rabbit (1:1400), Alexa Fluor 488-conjugated goat anti-chicken
(1:1400), Alexa Fluor 555-conjugated goat anti-mouse (1:1,600),
and Alexa Fluor 488-conjugated goat anti-rabbit (1:1400) (all from
Molecular Probes, Life Technologies). Nuclei were counterstained
with 0.8 ng/mL Hoechst, diluted in PBS. In each experiment, five
fields/well (corresponding to about 150−200 cells/well) were counted
with a 60× objective by a Leica DMIRB inverted fluorescence
microscope. Positive cells for each marker were counted, and their
percentage was calculated over total viable cells.
Cytotoxicity Assay. To assess the potential cytotoxic effect of
trazodone on NPC and their progeny, cells were plated for
differentiation on laminin-coated flat bottom 96-well plates (Falcon)
at the density of 43 750 cells/cm2. Cells were treated with indicated
trazodone concentration or vehicle for 24 h. Cytoxicity was evaluated
using CellTox Green Cytotoxicity Assay (Promega) according to
manufacturer’s instructions. Positive control for membrane damage
was 0.8% Triton X-100 (Sigma) and four replicates for each condition
were measured. Fluorescent signal was read by VICTOR Multilabel
Plate Reader platform. The cytotoxicity results are expressed as relative
fluorescent units (RFU). Apoptotic rate was determined as previously
described.44
LC-ESI-MS Analysis. LC-ESI-MS analyses were carried out using a
Thermo Finnigan LCQ Deca XP Plus system equipped with a
quaternary pump, a Surveyor AS autosampler, and a vacuum degasser
(Thermo Finnigan, San Jose,̀ CA). The liquid chromatography was
performed on a Phenomenex Luna HILIC column (150 mm × 2 mm,
3 μm) with a Phenomenex Luna HILIC security guard column (4 mm
× 2 mm), at 25 °C, at 200 μL/min flow rate, under isocratic elution.
The mobile phase was composed of a 90:10 ratio of acetonitrile and
water (both with 0.2% v/v of formic acid). The injection volume was 5
μL, and the run time was 20 min. The MS detection of serotonin was
performed in positive ionization mode. Quantitation was carried out
using single reaction monitoring (SRM) mode to monitor the
transition m/z 177 > 160 (collision-induced dissociation, CID 22 eV).
The principle instrument parameters were set as follows: ion spray
voltage, 5.2 kV; source current, 80 μA; capillary temperature, 350 °C.
Sample Preparation for LC-ESI-MS Analysis. Vehicle- or
PCPA-treated ahNPCs were differentiated in the presence of vehicle,
trazodone, or fluoxetine. Differentiation media were collected after 24
h and centrifuged for 10 min at 16 000g. Acetonitrile (140 μL) with
0.2% of formic acid was added to 60 μL of collected media. Proteins
were precipitated by centrifugation for 10 min at 11 300g. An aliquot
of 180 μL of supernatant was evaporated to dryness in a rotational
vacuum concentrator (for about 4 h at 40 °C). The sample was
reconstituted in 80 μL of water/acetonitrile with 0.2% of formic acid
(3:7 vol/vol), before the injection. For quantification of serotonin in
differentiation medium, a calibration curve was prepared in blank
matrix (differentiation medium treated with acetonitrile with 0.2% of
formic acid, 3:7 vol/vol) in the appropriate range.
Statistical Analysis. All experiments were run in triplicate using
different cell preparations and repeated at least three times. Data were
expressed as mean ± SD and analyzed by one-way analysis of variance
(ANOVA), followed by Tuckey’s post hoc test or by Student’s t test.
Statistical significance level was set for p values <0.05.
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